Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $108.50 USD
Change Today -0.71 / -0.65%
Volume 6.0K
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

mesa laboratories inc (MLAB) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/3/15 - $126.05
52 Week Low
09/23/14 - $54.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MESA LABORATORIES INC (MLAB)

Related News

No related news articles were found.

mesa laboratories inc (MLAB) Related Businessweek News

No Related Businessweek News Found

mesa laboratories inc (MLAB) Details

Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products. It operates through three segments: Instruments, Biological Indicators, and Continuous Monitoring. The Instruments segment offers data loggers, a precision instrument that are used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the proper calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment, which are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring for various organizations; and torque testing systems used for the packaging industry. Its products are used in healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling, and semiconductor industries. The Biological Indicators segment manufactures and markets biological indicators comprising spore strips, self-contained products, and culture media, as well as process challenge devices. This segment also distributes chemical indicators that are used to assess the effectiveness of sterilization processes, including steam, hydrogen peroxide, ethylene oxide, and radiation in the hospital, dental, medical device, and pharmaceutical industries. The Continuous Monitoring segment designs, develops, and markets systems, which are used to monitor various environmental parameters, such as temperature, humidity, and differential pressure for use in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and various other laboratory and industrial environments. The company markets its products through distributors in the United States, Europe, Africa, Asia, South America, Australia, Canada, and Central America. Mesa Laboratories, Inc. was founded in 1982 and is headquartered in Lakewood, Colorado.

276 Employees
Last Reported Date: 06/3/15
Founded in 1982

mesa laboratories inc (MLAB) Top Compensated Officers

Chief Executive Officer, President, Treasurer...
Total Annual Compensation: $316.5K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $214.3K
Chief Sales & Marketing Officer and Executive...
Total Annual Compensation: $212.7K
Senior Vice President of Operations
Total Annual Compensation: $160.0K
Senior Vice President of Operations
Total Annual Compensation: $160.0K
Compensation as of Fiscal Year 2015.

mesa laboratories inc (MLAB) Key Developments

Mesa Laboratories, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Mesa Laboratories Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, revenues increased 11% to $18,158,000 as compared to $16,400,000 for the same quarter last year. Operating income increased 19% to $3,642,000 as compared to $3,055,000 for the same quarter last year. Net income increased 23% to $2,306,000 or $0.63 per diluted share of common stock as compared to $1,881,000 or $0.51 per diluted share of common stock for the same quarter last year. On a non-GAAP basis, adjusted net income (which excludes the non-cash impact of amortization of intangible assets, net of tax) increased 20% to $3,137,000 or $0.85 per diluted share of common stock as compared to $2,612,000 or $0.71 per diluted share of common stock for the same quarter last year. Earnings before income taxes was $3,526,000 compared to $2,893,000 a year ago.

Mesa Labs Declares Quarterly Dividend Payable on September 15, 2015

Mesa Laboratories Inc. announced that its board of directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2015, to shareholders of record at the close of business on August 31, 2015.

Mesa Laboratories, Inc. Further Amends its Credit Facility with JPMorgan Chase Bank

On July 1, 2015, Mesa Laboratories Inc. further amended its Credit Facility with JPMorgan Chase Bank, N.A. The significant modifications in the amendment include the extension of the maturity date from June 30, 2017 to June 30, 2020, an increase in the revolving line of credit from $20.0 million to $50.0 million and the establishment of a $20.0 million term loan. The majority of the proceeds from the Term Loan were used to pay down the company's existing $12.0 million term loan. The Line of Credit bears interest at either: (1) LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25% or (2) the bank's commercial bank floating rate, which is the bank's prime rate adjusted down by 0.50%. The company elects the interest rate with each borrowing under the Line of Credit. In addition, there is an unused line fee of 0.25%. The Term Loan bears interest at LIBOR plus an applicable margin ranging from 1.5% to 2.25% and requires 20 quarterly principal payments (the first due date being July 15, 2015) in the amount of $750,000 with the remaining balance of principal and accrued interest due on June 30, 2020. The covenant requirements under the Credit Facility were modified as such that the ratio of funded debt to EBITDA, as defined is not to exceed 3.25 to 1.0 through March 31, 2016 and 3.0 to 1.0 thereafter, as compared to 2.5 to 1.0 in the previous amendment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MLAB:US $108.50 USD -0.71

MLAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $139.84 USD -1.90
Amphenol Corp $50.75 USD -1.23
Danaher Corp $85.59 USD -1.29
STERIS Corp $63.50 USD -0.73
Thermo Fisher Scientific Inc $121.17 USD -1.60
View Industry Companies

Industry Analysis


Industry Average

Valuation MLAB Industry Range
Price/Earnings 40.8x
Price/Sales 5.5x
Price/Book 5.3x
Price/Cash Flow 40.1x
TEV/Sales 5.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MESA LABORATORIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at